Skip to main content
Premium Trial:

Request an Annual Quote

Bar Harbor BioTechnology Wins $330K Award from Maine Technology Institute

Bar Harbor BioTechnology announced that it has won a development award from the Maine Technology Institute. The award, worth $334,632, will help the privately held company develop human genetic profiling products.

The award "will enable us to develop new products specifically applied to study gene profile changes during human disease states and genetic risk assessment," said company CSO Derry Roopenian in a statement.

Bar Harbor BioTechnology was founded in September 2006 by scientists from Jackson Laboratories in Maine with the goal of building gene detection arrays as well as bioinformatics resources and tools for molecular profiling.

The company expects to launch its first group of products for gene expression and copy number profiling on October 1st.

"BHB's first generation of computational and consumable products bridge the gap between basic, mouse-based research and human diseases, allowing for a more rapid translation of the lab bench to the bedside," said Dan Shaffer, VP of production, in a statement.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.